July 29 (Bloomberg) — Swine flu vac­cine mak­ers may rely on a U.S. emer­gency dec­la­ra­tion to use exper­i­men­tal addi­tives made by Glax­o­SmithK­line Plc and Novar­tis AG to boost a lim­ited sup­ply of shots that will be avail­able to fight the pandemic.

The ingre­di­ents, known as adju­vants, may be added for the first time to flu shots in the U.S. Health offi­cials, meet­ing today at the U.S. Cen­ters for Dis­ease Con­trol and Pre­ven­tion in Atlanta, plan to dis­cuss use of the addi­tives, and may also rec­om­mend who should be first to receive the lim­ited amount of vac­cines drug­mak­ers say they will begin deliv­er­ing in October.

The U.S. Health and Human Ser­vices Depart­ment declared a pub­lic health emer­gency over swine flu in April, and the Food and Drug Admin­is­tra­tion has the power to allow the use of unap­proved med­ical prod­ucts dur­ing such a cri­sis. The U.S. has been slow to approve the use of adju­vants because of safety con­cerns, and for fear of giv­ing Amer­i­cans an excuse to avoid get­ting the shots, said John Tre­anor, a Uni­ver­sity of Rochester researcher. [ … ]

» Read more: Swine Flu Shot in U.S. May Rely on Emer­gency Use of Additives